Silkstone V L, Corlett S A, Chrystyn H
School of Pharmacy, University of Bradford, Bradford BD7 1DP, UK.
Br J Clin Pharmacol. 2002 Aug;54(2):115-9. doi: 10.1046/j.1365-2125.2002.01632.x.
Clinical studies comparing nebulized drug delivery systems could be flawed because of the high doses used. We have compared lung and total systemic delivery of salbutamol from a nebuliser with that from a metered dose inhaler by measuring urinary recovery of drug and its sulphate metabolite.
Twelve healthy volunteers provided urine samples at 0, 0.5, 1, 2, 4, 8, 12 and 24 h after the start of dosing. Formulations and doses were 5 x 100 microg oral solution (ORAL), 5 x 100 microg from a metered dose inhaler (MDI), 2.5 mg using a nebuliser (NEB) and NEB with 25 g oral charcoal (NEBC). Each study phase was separated by 7 days and the order of dosing was randomized.
Mean (s.d.) 30 min urinary salbutamol excretion after ORAL, MDI, NEB and NEBC was 0.4 (0.7), 12.1 (3.7), 15.0 (3.9) and 18.2 (5.7) microg, respectively (all P<0.001 compared with ORAL). When normalized for the dose available for inhalation from MDI, NEB and NEBC, the mean (s.d.) 30 min urinary excretion of salbutamol was 2.4 (0.7), 2.9 (0.6) and 2.7 (0.6)%, respectively, with a mean ratio (90% confidence interval) between NEB and NEBC, of 95.3 (91.1, 99.5)%. The mean (s.d.) excretion of salbutamol plus its metabolite over 24 h post ORAL, MDI, NEB and NEBC dosing was 297.9 (38.3), 290.3 (41.4), 266.5 (44.6) and 151.7 (40.9) microg, respectively. The mean ratio (90% confidence interval) between MDI and ORAL, and NEB and ORAL were 97.5 (94.1, 101.0) and 90.7 (81.2, 100.2)%, respectively. The NEBC data indicate that 6.07 (1.04)% of the nominal nebulized dose was delivered to the lungs.
The 30 min urinary recovery of salbutamol, an index of the relative systemic bioavailability of salbutamol following inhalation, can be used to compare the lung deposition of nebulized systems. Similarly, the urinary 24 h recovery of salbutamol plus its metabolite, an index of the relative systemic bioavailability of salbutamol following inhalation, can be used to compare the delivery of nebulized drug to the systemic circulation.
由于使用的剂量较高,比较雾化药物递送系统的临床研究可能存在缺陷。我们通过测量药物及其硫酸盐代谢物的尿回收率,比较了雾化器和定量吸入器中沙丁胺醇的肺部和全身递送情况。
12名健康志愿者在给药开始后的0、0.5、1、2、4、8、12和24小时提供尿液样本。制剂和剂量分别为5×100微克口服溶液(ORAL)、5×100微克定量吸入器(MDI)、2.5毫克雾化器(NEB)和含25克口服活性炭的雾化器(NEBC)。每个研究阶段间隔7天,给药顺序随机。
口服、MDI、NEB和NEBC后30分钟尿沙丁胺醇排泄量的平均值(标准差)分别为0.4(0.7)、12.1(3.7)、15.0(3.9)和18.2(5.7)微克(与口服相比,所有P<0.001)。当以MDI、NEB和NEBC可吸入剂量进行标准化时,沙丁胺醇30分钟尿排泄量的平均值(标准差)分别为2.4(0.7)%、2.9(0.6)%和2.7(0.6)%,NEB和NEBC之间的平均比值(90%置信区间)为95.3(91.1,99.5)%。口服、MDI、NEB和NEBC给药后24小时内沙丁胺醇及其代谢物的平均(标准差)排泄量分别为297.9(38.3)、290.3(41.4)、266.5(44.6)和151.7(40.9)微克。MDI与口服以及NEB与口服之间的平均比值(90%置信区间)分别为97.5(94.1,101.0)%和90.7(81.2,100.2)%。NEBC数据表明,名义雾化剂量的6.07(1.04)%递送至肺部。
沙丁胺醇30分钟尿回收率是吸入后沙丁胺醇相对全身生物利用度的指标,可用于比较雾化系统的肺部沉积。同样,沙丁胺醇及其代谢物24小时尿回收率是吸入后沙丁胺醇相对全身生物利用度 的指标,可用于比较雾化药物向体循环的递送情况。